ELIMINATION OF CHRONIC PELVIC PAIN CAUSED BY ADENOMYOSIS THE PROGESTOGENS NEW GENERATION

Mekan R. Orazov, A. V. Chayka, О. М. Носенко
In: Акушерство, гинекология и репродукция, Vol 8, Iss 3, Pp 6-10 (2016) · 2016 · W4298134077
article OA: green CC0 ⤵ 1 in-corpus citation
🔓 Open OA copy Full text JSON View on OpenAlex
⚙ AI-generated summary by claude@2026-06, 2026-06-13 ⓘ

This study evaluated the effectiveness and tolerance of 2mg daily dienogest for 6 months in 44 women with adenomyosis-related chronic pelvic pain, finding high therapeutic efficiency.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-13 · read from full text ⓘ

This study evaluated the clinical effectiveness and tolerability of dienogest, a new-generation progestogen, for resolving chronic pelvic pain syndrome in women diagnosed with adenomyosis. Forty-four reproductive-age women (mean age about 36 years) received dienogest 2 mg daily for 6 months, with adenomyosis severity ranging from mild to severe. The authors report high therapeutic efficiency of dienogest in treating pelvic pain caused by adenomyosis, while the abstract does not describe key methodological details or explicit limitations. This paper is centrally about adenomyosis — it focuses on eliminating chronic pelvic pain due to adenomyosis using dienogest.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Endometriosis, with more than centenary history, remains a challenge in our day. One of the more common options is adenomyosis, the share of which amounts to 80%. The aim of the study was to evaluate the clinical effectiveness and tolerance to resolve with chronic pelvic pain syndrome of adenomyosis the use of progestogen-new generation dienogest in a dose of 2 mg for 6 months. The study included 44 (n=44) women of reproductive age with a diagnosis of adenomyosis with chronic pelvic pain syndrome of various degrees of severity, whose average age was on average 36 yo 2 years who received therapy with dienogest in a daily dose of 2 mg for 6 months. The results showed high therapeuticefficiency dienogest in the treatment of pelvic pain caused by adenomyosis.
Full text 912 characters · extracted from oa-html · click to expand
Акушерство, гинекология и репродукция (Jun 2016) ELIMINATION OF CHRONIC PELVIC PAIN CAUSED BY ADENOMYOSIS THE PROGESTOGENS NEW GENERATION Abstract Endometriosis, with more than centenary history, remains a challenge in our day. One of the more common options is adenomyosis, the share of which amounts to 80%. The aim of the study was to evaluate the clinical effectiveness and tolerance to resolve with chronic pelvic pain syndrome of adenomyosis the use of progestogen-new generation dienogest in a dose of 2 mg for 6 months. The study included 44 (n=44) women of reproductive age with a diagnosis of adenomyosis with chronic pelvic pain syndrome of various degrees of severity, whose average age was on average 36 yo 2 years who received therapy with dienogest in a daily dose of 2 mg for 6 months. The results showed high therapeuticefficiency dienogest in the treatment of pelvic pain caused by adenomyosis.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosisadenomyosischronic_pelvic_pain

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (1)

Cited by (1)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK